Izokibep Ph2b/3 RCT PsA 340+ Primary endpoint ACR50 wk 16 IZO 160 mg Q2W 43% IZO 160 mg QW 40% PBO 15% Effect early as wk 4 PASI100 IZO Q2W 47% IZO QW 51% PBO 12% Safety profile similar to IL-17i @RheumNow #EULAR2024 LBA0005 https://t.co/vWRQ1ECrAX